The Global Influenza Diagnostics Market is expected to register a CAGR of 7.80% to reach USD 954.512 million by 2023. , Influenza is a contagious respiratory infection caused by several flu viruses. Pandemics influenza is a new flu virus strain that can easily spread from one person to another. Every year seasonal influenza affects millions of people and causes thousands of hospitalizations and flu-related deaths. Increasing aging patient population, the introduction of quadrivalent influenza vaccines, and rising disease awareness drive the growth of the global influenza diagnostics market. However, stringent regulatory policies may hamper the growth of the market., Synopsis/Market Dynamics, Influenza is a condition which is commonly known as seasonal flu. It is an infectious disease caused by the influenza virus. The most common symptoms include high fever, sore throat, headache, coughing, and sneezing. Influenza spreads across the world in seasonal outbreaks. About 3 to 5 million cases of severe illness are reported every year. However, factors such as the rising prevalence of influenza, increasing research funding for influenza diagnostics, and growing demand for quick diagnostic tests may hamper the growth of the market during the forecast period., Influenza is a highly infectious respiratory ailment. The global influenza pandemics that occurred in the twentieth century caused more than 5,00,000 deaths in the US and nearly 50 million deaths worldwide. It is a major threat to public health. According to the National Institute of Health Report 2016, more than 2,00,000 patients were hospitalized due to influenza virus. It mostly affects people with a weak immune system, i.e., the pediatric and geriatric population. Globally there are about 3 to 5 million cases of severe influenza. As per the National Influenza Centers (NICs) Report 2018, 69,007 people were diagnosed with influenza viruses out of which 67,733 were diagnosed with the influenza A virus and 1,274 with the influenza B virus, respectively. According to the World Health Organization Report 2017, the influenza virus is continuously growing in the South-East Asia region. Globally, 91% of the population were diagnosed with the influenza A virus out

The Global Influenza Diagnostics Market is expected to register a CAGR of 7.80% to reach USD 954.512 million by 2023.

Influenza is a contagious respiratory infection caused by several flu viruses. Pandemics influenza is a new flu virus strain that can easily spread from one person to another. Every year seasonal influenza affects millions of people and causes thousands of hospitalizations and flu-related deaths. Increasing aging patient population, the introduction of quadrivalent influenza vaccines, and rising disease awareness drive the growth of the global influenza diagnostics market. However, stringent regulatory policies may hamper the growth of the market.

Synopsis/Market Dynamics

Influenza is a condition which is commonly known as seasonal flu. It is an infectious disease caused by the influenza virus. The most common symptoms include high fever, sore throat, headache, coughing, and sneezing. Influenza spreads across the world in seasonal outbreaks. About 3 to 5 million cases of severe illness are reported every year. However, factors such as the rising prevalence of influenza, increasing research funding for influenza diagnostics, and growing demand for quick diagnostic tests may hamper the growth of the market during the forecast period.

Influenza is a highly infectious respiratory ailment. The global influenza pandemics that occurred in the twentieth century caused more than 5,00,000 deaths in the US and nearly 50 million deaths worldwide. It is a major threat to public health. According to the National Institute of Health Report 2016, more than 2,00,000 patients were hospitalized due to influenza virus. It mostly affects people with a weak immune system, i.e., the pediatric and geriatric population. Globally there are about 3 to 5 million cases of severe influenza. As per the National Influenza Centers (NICs) Report 2018, 69,007 people were diagnosed with influenza viruses out of which 67,733 were diagnosed with the influenza A virus and 1,274 with the influenza B virus, respectively. According to the World Health Organization Report 2017, the influenza virus is continuously growing in the South-East Asia region. Globally, 91% of the population were diagnosed with the influenza A virus out of which 9% were associated with the influenza B virus. The worst flu outbreak on record occurred in 2015, during which 7,10,000 US citizens were hospitalized due to swine flu with a death toll of 56,000 citizens. Hence, the prevalence of influenza is increasing every year.

Global Influenza Diagnostics Market Revenue, by Type of Flu, 2017 (USD Million)

Sources: MRFR Analysis

Segmentation

The type A flu segment is expected to lead the market and register a substantial CAGR to reach USD 954.512 million by the end of 2023. These viruses were responsible for very large annual epidemics in the past. However, the type B flu segment is projected to exhibit the highest CAGR of 8.66% from 2018 to 2023. Growing government initiatives to curb influenza and increased risk of contracting influenza are anticipated to drive market growth.

Global Influenza Diagnostics Market Share, by Region, 2017 (%)

Sources: MRFR Analysis

Regional Analysis

The Americas accounted for the largest market share of 38.0% in 2017. The Americas is estimated to dominate the global influenza diagnostics market during the forecast period. The market growth in this region is mainly due to the increasing prevalence of influenza among the geriatric population and advanced healthcare facilities in this region

The European market for influenza diagnostics is expected to be the second-largest during the review period. The increasing number of pharmaceutical companies exporting their products outside or within Europe is expected to contribute to market growth. The factors responsible for the market growth in this region are increased disease awareness, extended recommendations by governmental and advisory bodies to be vaccinated against influenza and an increase in the size of the elderly population. The influenza diagnostics market in Europe is expected to grow several folds in coming years due to several favorable factors such as the introduction of innovative technologies, favorable pricing, reimbursement, unmet medical necessities, and strong clinical pipeline.

Asia-Pacific is estimated to be the fastest growing market owing to the developing healthcare infrastructure. Due to the increasing prevalence of other diseases such as endocrinology, cardiovascular and lymphatic systems, as well as respiratory disorders, the market growth for influenza diagnostics is observed in this region.

Key Players

The prominent players in the global influenza diagnostics market are Abbott, Analytik Jena AG, Becton, Dickinson and Company, Biocartis, bioMérieux Inc, Cepheid, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, GenMark Diagnostics, Inc., Luminex Corporation, Meridian Bioscience, Inc., Quidel Corporation, SA Scientific, Thermo Fisher Scientific Inc.

Market Segmentation

Global Influenza Diagnostics Market, by Type of Flu



Type A Flu



Type B Flu



Type C Flu



Global Influenza Diagnostics Market, by Test Type



Traditional Diagnostic Tests



Molecular Diagnostic Tests



Global Influenza Diagnostics Market, by End User



Hospitals & Clinical Laboratories



Point-of-Care Testing



Global Influenza Diagnostics Market, by Region



North America



US

Canada

Mexico







Europe



Germany

UK

France

Spain

Italy

Rest of Europe







Asia-Pacific



China

India

Japan

Australia & New Zealand

Southeast Asia

Rest of Asia-Pacific







Rest of the World



Middle East

Africa

South America









Available Additional Customizations



Company Profiles of Other Key Players



Coris BioConcept



DiaSorin S.p.A



Alere Inc.



Lonza



Ortho-Clinical Diagnostics



Qiagen



Wako



End User Analysis (Example)

Technology Trends: Several diagnostic tests are available in the market for the diagnosis of influenza. Researchers in Japan have combined sensor technology with artificial intelligence to rapidly diagnose the influenza virus. Influenza is a highly contagious respiratory disease which affects millions of people. Although, scientists have been exploring numerous ways to diagnose influenza rapidly to prevent the outbreaks. To develop a better diagnostic test for influenza, researchers in Japan have designed a sensor that can assess the nanoscale properties of influenza virus in patient samples. These sensors are made of silicon nitride and comprise small pores through which virus particles can pass. The research team found that the motion of the liquid medium can induce an electric current across the nanopore which is known as electro-osmotic flow. This could block the passage of non-virus particles in a sample, thereby increasing the sensitivity of its system. The sensor is estimated to give result in less than 15 minutes. This technology helps to reduce the therapeutic turnaround times (TAT), thus minimizing the time required for clinical decision and thereby reducing pre and post-analytic testing errors. These qualities of nanosensors help in replacing centralized laboratory testing and create immense demand for this diagnostic test in the global market. Due to the increasing prevalence of influenza among geriatric patients, these diagnostic tests are highly in demand.

Intended Audience





Influenza Diagnostics Solution providers



Diagnostic suppliers



Medical Research Laboratories



Research and Development (R&D) Companies



Market Research and Consulting Service Providers



Potential Investors



Frequently Asked Questions (FAQ) :